9 results
10-K
2020 FY
NEXI
Neximmune Inc
31 Mar 21
Annual report
4:02pm
, and has determined that more than minimally manipulated products require clinical trials to demonstrate product safety and efficacy and the submission … , and the production facility must meet standards designed to assure product safety, purity and potency.
A reference biological product is granted 12
424B4
NEXI
Neximmune Inc
16 Feb 21
Prospectus supplement with pricing info
4:38pm
manipulated, and has determined that more than minimally manipulated products require clinical trials to demonstrate product safety and efficacy … and strength, and the production facility must meet standards designed to assure product safety, purity and potency.
A reference biological product
S-1/A
vtihgkp
8 Feb 21
IPO registration (amended)
7:29am
S-1
sf97 ebsg3
19 Jan 21
IPO registration
4:38pm
DRS/A
a9dmz865
15 Jan 21
Draft registration statement (amended)
12:00am
DRS
5ub1xt v60trhntu
14 Dec 20
Draft registration statement
12:00am
- Prev
- 1
- Next